Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$957.00 USD
+19.39 (2.07%)
Updated May 3, 2024 04:00 PM ET
After-Market: $958.14 +1.14 (0.12%) 5:14 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
REGN 957.00 +19.39(2.07%)
Will REGN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for REGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for REGN
Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y
Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
REGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
Other News for REGN
Assessing Regeneron Pharmaceuticals: Insights From 16 Financial Analysts
June 14th Options Now Available For Regeneron Pharmaceuticals (REGN)
Why Investors Are Eyeing Regeneron Pharmaceuticals Inc (REGN): The Key Drivers of Market ...
Analysts Are Bullish on These Healthcare Stocks: Elevation Oncology (ELEV), Moderna (MRNA)
Regeneron (REGN) Receives a Buy from Oppenheimer